Bimatoprost is under clinical development by Laboratoires Thea and currently in Phase III for Ocular Hypertension.
GlobalData on MSN3mon
Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapyNovaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye ...
About Théa Open Innovation Théa is the leading independent European pharmaceutical company specialized in the research, development, and commercialization of eye-care products. Based in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results